Breakthrough Blood Tests Offer Hope for Early Alzheimer’s Detection
Dementia, a devastating condition that robs individuals of their memories and cognitive abilities, is a significant health challenge in the UK, claiming over 75,000 lives annually. Historically, diagnosing conditions like Alzheimer’s, the most prevalent form of dementia, has often relied on the manifestation of pronounced symptoms, leading to delayed interventions. However, a paradigm shift may be on the horizon with the development of revolutionary blood tests designed to detect Alzheimer’s disease years, even decades, before symptoms even begin to surface.
The ultimate goal of these pioneering tests is to facilitate early diagnosis. This, in turn, could allow for timely lifestyle modifications, such as embracing regular exercise and a balanced diet, alongside the potential application of targeted medications. For many, particularly in the absence of a definitive cure, this proactive, early intervention is seen as the most promising strategy to combat Alzheimer’s.
Across the UK, nearly a million individuals are living with dementia. Shockingly, recent statistics reveal that dementia is now responsible for more deaths than cancer or cardiovascular diseases. This often occurs due to complications stemming from a compromised immune system, including pneumonia or difficulties with swallowing.
The challenge of late diagnosis is exacerbated by the fact that a significant portion of individuals – approximately one in four – delay seeking medical advice for dementia-related symptoms for two years or longer. Many attribute forgetfulness, confusion, and other cognitive changes to the natural process of ageing, thus missing crucial windows for intervention.
Currently, medical professionals diagnose Alzheimer’s through a combination of cognitive assessments, memory tests, and sophisticated imaging techniques like MRI and PET scans. These scans help identify the presence of protein deposits, known as plaques, in the brain, which are characteristic of the disease. However, the advent of these new blood tests promises to accelerate this diagnostic process by several years.
While most current diagnostic methods involve drawing blood from a vein in the arm, researchers are actively exploring less invasive alternatives. Notably, at least one research team is developing a finger-prick test, similar to those used by individuals with diabetes to monitor blood glucose levels. The intention is for these tests to be conducted conveniently at home, with the sample then posted to a laboratory for analysis.
Unlocking the Secrets of Early Alzheimer’s Markers
A significant breakthrough has emerged from Northwestern University in the United States, where researchers have identified specific toxic proteins, labelled ACU193+, in the brain. For the first time, these proteins have been definitively linked to the inflammation and cellular damage that are hallmarks of early-stage Alzheimer’s.
These crucial findings, published in the journal Alzheimer’s & Dementia, suggest that these problematic proteins can be detected in the bloodstream up to 20 years before any outward symptoms of the disease manifest.
Richard Silverman, a professor of chemistry at Northwestern and a senior author of the study, emphasised the critical importance of early treatment. “It’s important to be treated before symptoms appear because by then much neurodegeneration has already occurred,” he stated. “The promise of better early diagnostics before symptoms are apparent – combined with a drug that could stop the disease in its tracks – is the goal.”
The Evolving Landscape of Alzheimer’s Treatments
While a cure for Alzheimer’s remains elusive, existing treatments offer some relief. For years, medications such as cholinesterase inhibitors, like Aricept, have been available. These drugs work by enhancing the activity of acetylcholine, a vital chemical messenger in the brain responsible for memory and learning. While they can help manage symptoms and improve a patient’s quality of life, they do not halt the progression of the disease.
More recently, newer drugs like lecanemab and donanemab have shown promise in slowing the progression of Alzheimer’s in its initial stages, once symptoms have begun to appear. However, their widespread adoption on the NHS is currently limited. This is partly due to concerns that their benefits may not fully outweigh their costs and the potential for side effects, such as brain bleeds and swelling.
Intriguingly, the Northwestern University team that is developing the blood test has also identified a new drug, NU-9. This compound, already used in the treatment of motor neurone disease, has demonstrated an ability to neutralise the toxic ACU193+ proteins in mice. This discovery is fuelling optimism that NU-9 could potentially prevent, or significantly delay, the onset of Alzheimer’s in humans.
Promising Developments in Protein Detection
In parallel, another significant blood test, known as the Fujirebio Lumipulse assay, is undergoing evaluation. Doctors at University College Hospital in London have already utilised this test on approximately 1,000 individuals. The test focuses on detecting a protein called pTau217, which serves as a strong indicator of the presence of key Alzheimer’s disease markers in the brain, including tau tangles and amyloid plaques.
Professor Jonathan Schott, a leading neurologist at the University College London Institute of Neurology, highlighted the significance of pTau217. “There are hundreds of potential biomarkers, but pTau217 is definitely one of the most promising,” he commented. Professor Schott is actively involved in research investigating pTau217 as part of a broader initiative supported by UK dementia charities aimed at exploring the potential of blood tests for early diagnosis.
He further elaborated on the remarkable sensitivity of these emerging diagnostic tools. “We are now in the midst of conducting a clinical trial [on pTau217] in memory clinics, which we hope will provide the evidence that the National Institute for Health and Care Excellence needs to make these tests routinely available across the NHS,” he added. The sensitivity of these tests is so profound that they can detect minute concentrations of specific Alzheimer’s proteins in the blood, as low as one part per billion or even less. To illustrate this incredible precision, Professor Schott offered a compelling analogy: “To give you some idea of how sensitive these tests are, if you threw a grain of salt into an Olympic-sized swimming pool, these tests would detect it.”
Dr Richard Oakley, associate director of research and innovation at Alzheimer’s Society, acknowledged that the widespread, routine use of blood tests like the one being developed at Northwestern University is still some time away. However, he expressed strong optimism about their future impact. “They could transform how Alzheimer’s disease is diagnosed,” he stated. “Getting an accurate diagnosis currently takes far too long, and one in three people in the UK with dementia do not have a diagnosis. With new treatments on the horizon, early and accurate diagnosis must be a priority.”
For confidential advice and support regarding dementia, individuals can contact the Alzheimer’s Society’s Dementia Support Line on 0333 150 3456. The Alzheimer’s Society’s symptoms checker also offers a valuable resource for identifying potential signs of dementia.
